Therefore, it is not surprising that pharmacological strategies able to block the neurohormonal activation, such as inhibitors of the angiotensin converting enzyme (ACEi), angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRA) associated to significant benefits in cardiovascular outcomes (cardiovascular death and re-hospitalization for HF) in HFrEF, repeatedly showed evident trends toward a reduction in morbidity and mortality in other HF subsets characterized by a preserved LVEF (Ponikowski et al., 2016). This evidence concerns the gene NR3C2 and hydrops fetalis.